Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Director | February 15, 2026 | February 18, 2026 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director · Chief Executive Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,018 |
Reported balance
After 2026-02-15 transaction · row 1
1 source rowRow 1 · 2026-02-15 · Grant · Acquired 4,520 · Balance 9,018 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
SI-BONE, Inc.
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 379,256 |
Reported balance
After 2026-10-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 38,006 · Balance 379,256 F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026. F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr. F4: Shares held by The David & Laura Joint Rev Tr. |
| Common StockSEC Table I · non-derivative | Direct | 368,129 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 368,129 F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026.
F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr.
F4: Shares held by The David & Laura Joint Rev Tr.
F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 1,233 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectDavid and Laura Francis Joint Rev Trust | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 3,551 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.59 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 13,690 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 8,185 | $17.59 | $143,952.05 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 9 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,809 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $17.35 USD to $17.835 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 5,135 | $17.00 | $87,304.76 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 8 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,994 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $16.35 USD to $17.345 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 3,016 | $17.45 | $52,621.06 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 7 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,129 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $17.36 USD to $17.58 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,566 | $16.72 | $26,185.40 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,145 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.35 USD to $16.95 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 9,781 | $17.60 | $172,152.45 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,711 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $17.35 USD to $17.915 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 3,197 | $16.83 | $53,816.70 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,492 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $16.36 USD to $17.33 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,232 | $16.78 | $37,441.80 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,689 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $16.35 USD to $16.95 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,029 | $16.75 | $33,975.81 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549,921 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.36 USD to $16.95 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 21:19 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,044 | $16.56 | $17,289.48 |
DisclosureSEC source: 0001562180-25-001488 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,950 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.36 USD to $16.72 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:09 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 30,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000978 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 552,994 F3 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest, if at all, over two years beginning February 15, 2026, with the number of shares earned based on the Company's 2025 Net Revenue growth and Adjusted EBITDA. F4 · balance_after: Includes 540,562 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · balance_after: Reflects the transfer of shares from the Reporting Person to The David & Laura Francis Joint Rev Tr. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:09 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 91,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000978 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,415 F2 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest, if at all, over three years based on the Issuer's total shareholder return (TSR) as measured against the TSR of the company at the median of the range TSRs of a set of peer companies established by the Issuer as set forth in the grant. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:09 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 122,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000978 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,679 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest over four years beginning on February 15, 2025, and will be released in quarterly installments, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:10 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,227 | $12.62 | $28,106.74 |
DisclosureSEC source: 0001562180-24-007838 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,875 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $12.35 USD to $13.02 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · balance_after: Includes 295,932 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:10 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,563 | $12.59 | $19,670.67 |
DisclosureSEC source: 0001562180-24-007838 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,102 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $12.44 USD to $12.99 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:10 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,025 | $12.61 | $25,541.53 |
DisclosureSEC source: 0001562180-24-007838 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,665 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $12.35 USD to $12.99 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:10 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 3,191 | $12.48 | $39,837.72 |
DisclosureSEC source: 0001562180-24-007838 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,690 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.33 USD to $13.02 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 22:10 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,042 | $12.67 | $13,197.03 |
DisclosureSEC source: 0001562180-24-007838 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,881 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.42 USD to $12.99 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,550 | $13.85 | $21,473.55 |
DisclosureSEC source: 0001562180-24-006413 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,923 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.77 USD to $14.07 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · balance_after: Includes 315,737 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,034 | $13.86 | $14,333.41 |
DisclosureSEC source: 0001562180-24-006413 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,473 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.77 USD to $14.06 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,209 | $13.84 | $30,577.64 |
DisclosureSEC source: 0001562180-24-006413 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,507 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.77 USD to $14.08 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,009 | $13.84 | $27,799.54 |
DisclosureSEC source: 0001562180-24-006413 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,716 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.77 USD to $14.07 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:52 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 3,165 | $13.83 | $43,785.88 |
DisclosureSEC source: 0001562180-24-006413 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,725 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.77 USD to $14.08 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 00:20 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,392 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-24-005137 · primarydocument.xml · derivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,392 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on May 26, 2015, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 00:20 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,277 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001562180-24-005137 · primarydocument.xml · derivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,277 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on December 12, 2017, subject to Reporting Person's continued service through each relevant vesting date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 00:20 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 57,392 | $4.32 | $247,933.44 |
DisclosureSEC source: 0001562180-24-005137 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the transfer of shares from the Reporting Person to The David & Laura Francis Joint Rev Tr. F2 · balance_after: Includes 1,414 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2024. F3 · balance_after: Includes 335,545 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 00:20 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 11,277 | $4.68 | $52,776.36 |
DisclosureSEC source: 0001562180-24-005137 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:42 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerStock Option · Derivative | 13,690 | Not disclosed Strike: $6.59 | Not disclosed |
DisclosureSEC source: 0001642545-24-000122 · wk-form4_1717188121.xml · derivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,690 shares Expires 2029-02-01 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:42 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 3,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000122 · wk-form4_1717188121.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:42 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 1,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000122 · wk-form4_1717188121.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,500 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001642545-24-000081 · wk-form4_1711584251.xml · derivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,690 Underlying: Common Stock · 1,500 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,500 | $300.00 | $450,000.00 |
DisclosureSEC source: 0001642545-24-000081 · wk-form4_1711584251.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 3,551 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting person and the reporting persons spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000081 · wk-form4_1711584251.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 5,051 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting person and the reporting persons spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000081 · wk-form4_1711584251.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,233 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 00:04 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,500 | $6.59 | $9,882.00 |
DisclosureSEC source: 0001642545-24-000081 · wk-form4_1711584251.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:11 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionStock Option · Derivative | 1,000 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0001642545-24-000046 · wk-form4_1708477874.xml · derivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,190 Underlying: Common Stock · 1,000 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:11 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,000 | $250.00 | $250,000.00 |
DisclosureSEC source: 0001642545-24-000046 · wk-form4_1708477874.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 3,551 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting person and the reporting persons spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:11 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000046 · wk-form4_1708477874.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 4,551 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting person and the reporting persons spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:11 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000046 · wk-form4_1708477874.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:11 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,000 | $6.59 | $6,588.00 |
DisclosureSEC source: 0001642545-24-000046 · wk-form4_1708477874.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 05/23/2023. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 11,885 | $20.96 | $249,050.18 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 7 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,476 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 355,352 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 18,981 | $20.96 | $397,746.86 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,361 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,043 | $20.96 | $21,856.07 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,342 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,229 | $20.96 | $46,708.70 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,385 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,564 | $20.96 | $32,773.62 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 535,614 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,027 | $20.96 | $42,475.79 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537,178 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:22 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 858 | $20.96 | $17,979.39 |
DisclosureSEC source: 0001562180-24-001541 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,205 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.52 USD to $21.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 100,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000310 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 540,063 F2 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest, if at all, over three years based on the Issuer's total shareholder return (TSR) as measured against the TSR of the company at the median of the range TSRs of a set of peer companies established by the Issuer as set forth in the grant. F3 · balance_after: Includes 436,551 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · balance_after: Reflects the transfer of shares from the Reporting Person to The David & Laura Francis Joint Rev Tr. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 100,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000310 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,410 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest over four years beginning on January 1, 2024, and will be released in quarterly installments, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| October 02, 2023 Filed Dec 13, 2023 01:27 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 497 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058430 · doc4.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 3,551 F1 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting person and the reporting persons spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 02, 2023 Filed Dec 13, 2023 01:27 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 497 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058430 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233 F1 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.